Y-mAbs Therapeutics, Inc. Accrued Liabilities, Current
Y-mAbs Therapeutics, Inc. had Accrued Liabilities, Current of $14.89 million as of 2025-06-30, per its 10-Q filed 2025-08-08.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2025-08-08
- 2025-06-30: Accrued Liabilities, Current $14.89M.
- 2025-03-31: Accrued Liabilities, Current $13.88M.
- 2024-12-31: Accrued Liabilities, Current $16.41M.
- 2024-09-30: Accrued Liabilities, Current $16.64M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2025-06-30 | $14.89M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $13.88M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $16.41M 10-Q · filed 2025-08-08 |
| 2024-09-30 | $16.64M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $12.79M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $9.99M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $13.17M 10-K · filed 2025-03-04 |
| 2023-09-30 | $13.30M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $16.15M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $16.22M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $13.24M 10-K · filed 2024-02-29 |
| 2022-09-30 | $17.09M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $17.07M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $12.93M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $12.54M 10-K · filed 2023-03-30 |
| 2021-09-30 | $12.49M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $12.17M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $8.49M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $8.20M 10-K · filed 2022-03-01 |
| 2020-09-30 | $7.57M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $5.31M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $4.04M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $4.55M 10-K · filed 2021-03-01 |
| 2019-09-30 | $5.85M 10-Q · filed 2019-11-13 |
| 2019-06-30 | $4.21M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $3.88M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $3.25M 10-K · filed 2020-03-12 |
| 2018-09-30 | $2.49M 10-Q · filed 2018-11-13 |
| 2017-12-31 | $2.02M 10-K · filed 2019-03-22 |